Retirement Systems of Alabama Sells 373 Shares of Amedisys, Inc. (NASDAQ:AMED)

Posted by on Jul 28th, 2023

Retirement Systems of Alabama lowered its stake in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 0.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 42,453 shares of the health services provider’s stock after selling 373 shares during the period. Retirement Systems of Alabama owned approximately 0.13% of Amedisys worth $3,122,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Raymond James & Associates boosted its position in shares of Amedisys by 6.5% during the 1st quarter. Raymond James & Associates now owns 11,101 shares of the health services provider’s stock worth $1,913,000 after acquiring an additional 680 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in Amedisys by 9.2% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 2,397 shares of the health services provider’s stock worth $413,000 after acquiring an additional 202 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in Amedisys by 22.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,425 shares of the health services provider’s stock valued at $590,000 after purchasing an additional 620 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Amedisys by 40.4% during the first quarter. HighTower Advisors LLC now owns 7,619 shares of the health services provider’s stock valued at $1,310,000 after purchasing an additional 2,193 shares during the period. Finally, Citigroup Inc. boosted its position in shares of Amedisys by 6.4% during the 1st quarter. Citigroup Inc. now owns 13,268 shares of the health services provider’s stock worth $2,287,000 after purchasing an additional 803 shares in the last quarter. 94.85% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Stock Performance

NASDAQ:AMED opened at $90.50 on Friday. The firm has a market capitalization of $2.95 billion, a PE ratio of 26.31, a PEG ratio of 2.55 and a beta of 1.06. The stock’s fifty day moving average is $87.48 and its 200 day moving average is $85.10. Amedisys, Inc. has a fifty-two week low of $69.36 and a fifty-two week high of $129.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.15 and a current ratio of 1.15.

Amedisys (NASDAQ:AMED – Get Free Report) last released its quarterly earnings results on Wednesday, July 26th. The health services provider reported $1.37 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.28. Amedisys had a net margin of 5.02% and a return on equity of 14.35%. The firm had revenue of $552.97 million during the quarter, compared to analysts’ expectations of $568.18 million. During the same period in the previous year, the company earned $1.47 EPS. The firm’s revenue for the quarter was down .9% compared to the same quarter last year. On average, sell-side analysts anticipate that Amedisys, Inc. will post 4.24 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AMED shares. Credit Suisse Group cut Amedisys from an “outperform” rating to a “neutral” rating in a report on Tuesday, June 6th. Cantor Fitzgerald lifted their price objective on Amedisys from $91.00 to $100.00 in a report on Tuesday, June 6th. Barclays increased their target price on shares of Amedisys from $88.00 to $101.00 in a research note on Tuesday, June 27th. Benchmark downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a report on Tuesday, June 27th. Finally, Jefferies Financial Group cut Amedisys from a “buy” rating to a “hold” rating in a report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $110.21.

Amedisys Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.